Articles related to KIDNEY CANCER/RCC

Emerging evidence suggests microbiome composition may be associated with immunotherapy response, toxicity, and outcomes in kidney cancer. Experts caution that inconsistent methodologies and limited reproducibility continue to challenge microbiome biomarker development.

Statistical models incorporating individual clinical and tumor characteristics showed superior accuracy when validated against standardized clinical trial data compared to retrospective prediction tools.

Explore the latest insights from ASCO GU 2024 on first-line treatments for advanced renal cell carcinoma, including the effectiveness of combination therapies and the pressing need to address racial disparities in patient outcomes.

In the landmark KEYNOTE-564 trial, pembrolizumab has emerged as a pivotal advancement in kidney cancer treatment, offering hope by significantly prolonging survival in patients with high-risk ccRCC post-nephrectomy.

Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.

Belzutifan’s FDA approval, following the LITESPARK-005 trial results, represents a significant stride in treating advanced kidney cancer, offering a novel therapeutic option for patients who have exhausted standard treatments.